Cullinan Therapeutics Financials - Benzinga

Cullinan Therapeutics Inc

CGEMNASDAQ

Trade with Public

Trade with Public

$15.23

0.281.87%

近くで: Sep 28, 5:00 PM EST

$15.27

0.322.14%

プレマーケット: 5:10 AM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Cullinan Therapeutics Financials

Cullinan Therapeutics (CGEM) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cullinan Therapeutics Q2 EPS $(0.81) Beats $(0.85) Estimate

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.85) by 4.71 percent. This is a 24.3 percent increase over losses of $(1.07) per share

Benzinga Newsdesk

PRO
Cullinan Therapeutics Q1 EPS $(0.75) Beats $(0.87) Estimate

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.87) by 13.79 percent. This is a 1.35 percent decrease over losses of $(0.74) per share

Benzinga Newsdesk

Cullinan Therapeutics: Q4 Earnings Insights

Benzinga Insights

PRO
Cullinan Therapeutics Q4 EPS $(0.77) Beats $(0.82) Estimate

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.82) by 6.1 percent. This is a 5.48 percent decrease over losses of $(0.73) per share

Benzinga Newsdesk

PRO
Cullinan Therapeutics Q3 EPS $(0.77) Beats $(0.95) Estimate

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.95) by 19.37 percent. This is a 22.22 percent decrease over losses of $(0.63) per share

Benzinga Newsdesk

PRO
Cullinan Therapeutics Q2 EPS $(1.07) Misses $(0.84) Estimate

Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.84) by 26.93 percent. This is a 57.35 percent decrease over losses of $(0.68) per

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved